Angelo Dipasquale: Which patient may benefit from inclusion in an early-phase trial with next-generation immunotherapies?

Angelo Dipasquale, Medical Oncologist at the Humanitas Research Hospital, shared a post on LinkedIn:

“Which patient may benefit from inclusion in an early-phase trial with next-generation immunotherapies? Find out our experience with interesting observations and a handy prognostic nomogram for clinical practice.”

Read further.

Source: Angelo Dipasquale/LinkedIn